Regulatory Open Forum

 View Only
Expand all | Collapse all

Ask Me Anything Session: APL

  • 1.  Ask Me Anything Session: APL

    Posted 12-Dec-2018 13:25
    Hi Members,

    Recently, RAPS released it's quarterly article series focusing on current trends and best practices in Global Advertising, Promotion and Labeling (APL) regulations. Today, we have five APL experts, @Linda Pollitz, @Julie Batal, @Richard Lem, @Georgina Lee, and @John Wong who will be discussing the articles in real-time and available to answer your questions.

    Please use this thread to ask the experts your questions.

    Can't wait to read the discussions!

    Best,
    Emily​​​​​​​​​

    ------------------------------
    Emily Stamm
    Community Manager
    Regulatory Affairs Professionals Society®
    regex@raps.org
    ------------------------------


  • 2.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 13:27
    Thanks, everyone, for joining this discussion thread. The article series on Global Advertising, Promotion and Labeling Regulations includes (i) The Changing Regulatory Landscape, (ii) Labeling Issues, (iii) Promoting Accelerated Approval, (iv) Medical Device Patent Protection, (v) Mobile Applications, (vi) Australia's Regulatory OTC Framework, and (vii) Drug Advertising in Canada.

    ------------------------------
    Linda Pollitz RAC
    Senior Director, Regulatory Affairs, Advertising & Promotion
    Bedford MA
    United States
    ------------------------------



  • 3.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 13:30
    Hi Everyone! Thanks for joining the discussion.

    I wanted to give some background on the inspiration  for my article which explored the relationship  and synergies between Labeling and Advertising and Promotions. I have worked in several Labeling and Ad Promo organizations and appreciate the distinct differences between the 2 functions, but also how they are co-dependent. Close teamwork, communciation, and robust relationships is the key to providing the most accurate and data-driven labeling and helpful, compelling, and timely ad promo materials.

    ------------------------------
    Julie Batal
    VP, Head of Regulatory Labeling
    Shire
    Cambridge, MA USA
    ------------------------------



  • 4.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 13:32
    I should add that the article was co-authored by my colleague Kristen Heinlein, the Head of Shire's ​US Ad Promo group!

    ------------------------------
    Julie Batal
    VP, Head of Regulatory Labeling
    Shire
    Cambridge, MA USA
    ------------------------------



  • 5.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 13:28
    HI all,

    Any questions about Canadian Drug Advertising regs, let me know...

    ------------------------------
    John Wong
    Director Regulatory Drug Advertising & Promotion
    Oakville ON
    Canada
    ------------------------------



  • 6.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 13:30
    Hi Reg Ex colleagues! Thanks for joining today's session to discuss global APL regulations. Rich and I collaborated on an article in RF titled the 'The Changing Regulatory Landscape of Advertising and Promotion" regarding the advent of the two final guidance documents (payer and CFL communications) and its impact on day to day interactions based on two fictional case studies. I am happy to join today's discussion about our article and about any other topics that arise. My area of expertise is focused on <g class="gr_ gr_1137 gr-alert gr_spell gr_inline_cards gr_run_anim ContextualSpelling multiReplace" id="1137" data-gr-id="1137">labeling</g>, advertising and promotion. Look forward to chatting soon!

    ------------------------------
    Georgina Lee PharmD
    Cambridge MA
    United States
    ------------------------------



  • 7.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 13:34
    Hi everyone, glad to be joining in the discussion today! I will also be contributing from an advertising and promotion perspective.

    Given the amount of changes that have occurred in the advertising and promotion space in the past few years, I hope that this session recognizes the complexities and nuances of what we each encounter on a day to day basis. Look forward to seeing your questions below!

    ------------------------------
    Richard Lem
    Whippany NJ
    United States
    ------------------------------



  • 8.  RE: Ask Me Anything Session: APL

    This message was posted by a user wishing to remain anonymous
    Posted 12-Dec-2018 13:34
    This message was posted by a user wishing to remain anonymous

    is there a live chat, or webex type link, or is it just the discussion on this thread?


  • 9.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 13:35
    This discussion will take place right here in this thread.

    ------------------------------
    Emily Stamm
    Community Manager
    Regulatory Affairs Professionals Society®
    regex@raps.org
    ------------------------------



  • 10.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 13:39
    If webinar or presentation recordings are available to the public online, what needs to be reviewed and approved by Regulatory prior to distribution? Slide content, transcription of audio, or both?

    ------------------------------
    Julie Meyer
    Regulatory Affairs
    Wayland IA
    United States
    ------------------------------



  • 11.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 13:41
    Hi Julie,

    If a webinar or presentation is recorded, and there is a desire to share the recording online, (and assuming we are speaking about a product - specific webinar or presentation), I would suggest that the whole review team review both the slide content and the transcript of the audio.

    ------------------------------
    Richard Lem
    Whippany NJ
    United States
    ------------------------------



  • 12.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 13:42
    To add to Rich's response, I would also recommend reviewing the websites that the webinar or presentation recordings will be posted on as well. Note any social media rules if the webinar or presentations are being posted on sponsored social media pages.

    ------------------------------
    Georgina Lee PharmD
    Cambridge MA
    United States
    ------------------------------



  • 13.  RE: Ask Me Anything Session: APL

    This message was posted by a user wishing to remain anonymous
    Posted 12-Dec-2018 13:46
    This message was posted by a user wishing to remain anonymous

    I'm interested in social media challenges and options as it relates to APL regulations (e.g. how does FDA regulate this? What are sponsors generally finding as acceptable approaches? Where can I learn more about this topic? Etc.)


  • 14.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 13:47
    RAPS Focus has had articles in the past couple of years covering social media. In addition, check out 3 FDA Guidances: (1) 2014-01-13_Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics (https://www.fda.gov/downloads/drugs/guidances/ucm381352.pdf), (2) 2014-06_Draft Guidance-Internet and Social Media Platforms with Character Space Limitations-Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices (https://www.fda.gov/downloads/drugs/guidances/ucm401087.pdf), and (3) 2014-06_Draft Guidance-Internet and Social Media Platforms-Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical Devices (https://www.fda.gov/downloads/drugs/guidances/ucm401079.pdf)

    ------------------------------
    Linda Pollitz RAC
    Senior Director, Regulatory Affairs, Advertising & Promotion
    Bedford MA
    United States
    ------------------------------



  • 15.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 13:59
    I would also add that the social media vendor could come visit and give you an overview of the platform's functionality. Understanding how the platform works can contextualize how to apply the draft guidances Linda posted above.

    ------------------------------
    Richard Lem
    Whippany NJ
    United States
    ------------------------------



  • 16.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 13:57
    John,
    How does it work in Canada? If a company wanted to promote their newly approved cancer drug on Facebook, are there guidelines or restrictions?

    ------------------------------
    Linda Pollitz RAC
    Senior Director, Regulatory Affairs, Advertising & Promotion
    Bedford MA
    United States
    ------------------------------



  • 17.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 14:05
    In Canada, Section C.01.044 of the regulations (Food & Drugs Act) prohibits direct-to-consumer (DTC) prescription drug advertising beyond the drug's name, price and quantity. So since social media (e.g. facebook..) is open to the public, it would not be feasible to host a chat room about a cancer drug as discussion will refer to disease condition and go beyond the restrictions. There is also restrictions on advertising of treatments about cancer and other serious disease to consumers (Section 3(1) of the Act).

    ------------------------------
    John Wong
    Director Regulatory Drug Advertising & Promotion
    Oakville ON
    Canada
    ------------------------------



  • 18.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 13:50
    Any updates or impending changes to the regulations specific to marketing claims being made via social media or digital marketing?

    ------------------------------
    Julie Meyer
    Regulatory Affairs
    Wayland IA
    United States
    ------------------------------



  • 19.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 13:51
    To my knowledge, there are no planned guidance documents for the remainder of 2018 from CDER (link: https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm417290.pdf) related to social media activity. That being said, I would subscribe to FR notices, OPDP and FDA guidance document updates in case any updates arise or new OPDP research activities arise that could inform future development of social media guidances.

    ------------------------------
    Georgina Lee PharmD
    Cambridge MA
    United States
    ------------------------------



  • 20.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 13:55
    1) How does FDA define advertisement and promotion?
    2) There are various guidance for pharma but not much for med device ad and promo. Please share industry best practices for developing a robust add and promo SOP.
    3) What questions should one ask while conducting review of add/promo material specially if the device is not approved yet?

    ------------------------------
    Jyoti Singh
    San Jose CA
    United States
    ------------------------------



  • 21.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 13:57
    Hi Jyoti, thanks for your questions! You can find more resources from FDA on advertising and promotion here: https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm109905.htm#Federal%20Food,%20Drug%20and%20Cosmetic%20Act

    ------------------------------
    Richard Lem
    Whippany NJ
    United States
    ------------------------------



  • 22.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 13:58
    To add to Rich's response, as you develop an SOP for the review and approval of advertising and promotional materials, some questions you'll want to ask/answer in your SOP include: (1) will you be reviewing materials for both marketed and investigational devices? for investor relations or corporate communications? (if no to the latter, be sure to exempt them), (2) details your process (eg,who comprises your review team and what are they responsible for reviewing per function; do you have standards for 'review readiness' of your materials, expedited reviews, concept reviews etc.), (3) expectations that consensus must be reached amongst reviewers, and in cases where this cannot be achieved, what your arbitration process entails; (4) records retention, (5) any limitations, (6) explanation of responsibilities of each function and (6) if the scope includes training materials related to how the advertising and promotion materials are to be used in the field.

    As for guidance on what can be said about unapproved devices, be sure to familiarize yourself with FDA's June 2018 Guidance on Communications with Payors, Formulary Committees and the like (https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm537347.pdf)

    ------------------------------
    Linda Pollitz RAC
    Senior Director, Regulatory Affairs, Advertising & Promotion
    Bedford MA
    United States
    ------------------------------



  • 23.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 14:03
    Hello, thank you so much for providing this opportunity to ask questions. 
    I noticed that there were a few questions posted in the previous thread that was started to announce this session. Will you be addressing those questions here, or in a later response? 
    Thank you!

    ------------------------------
    Susan Shockey RAC
    Regulatory Affairs and Quality Management
    [Charleston SC
    United States
    ------------------------------



  • 24.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 14:13
    Hi Susan,

    Thanks for joining us. We are doing our best to address all of the questions we received. If you have a specific questions or are looking for a question from previous threads to be answered feel free to re-post the question here or send me a message. 

    Best,
    Emily

    ------------------------------
    Emily Stamm
    Community Manager
    Regulatory Affairs Professionals Society®
    regex@raps.org
    ------------------------------



  • 25.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 14:10
    Hi experts! Has anyone had experience with annotating a redline draft label to FDA with a reference to another approved label? For example, in addition to providing the annotation of a specific sentence in the USPI to a source document (i.e., the relevant Module 2 summary), would it be appropriate to reference another label that contains similar language to what is being proposed?

    ------------------------------
    Georgina Lee PharmD
    Cambridge MA
    United States
    ------------------------------



  • 26.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 14:14
    The content that I included in annotations are references specifically to data to support labeling claims. If what you are doing is annotating to preferred language around the claim, that is not something I would annotate.

    ------------------------------
    Julie Batal
    VP, Head of Regulatory Labeling
    Cambridge, MA USA
    ------------------------------



  • 27.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 14:14
    This question was posted by a user who wished to remain anonymous:

    We are manufacturing a device that is made of both resorbable and non-resorbable materials. We used to call this 'partially resorbable' and market the device as such in the EU. After several years of marketing the device in EU, we are submitting the device for clearance in the US process and FDA found fault with the term of partial resorbability and want us to remove any such statements. As there is a non-resorbable component, we are fine with adjusting our labeling accordingly, but marketing wants to keep the term 'partially resorbable' for non-US markets.
    If we follow marketing's wish, this would result in us labeling/advertising the device differently in different countries - could this get us into trouble, i.e. would we have to adjust all labeling and marketing materials worldwide?

     



    ------------------------------
    Emily Stamm
    Community Manager
    Regulatory Affairs Professionals Society®
    regex@raps.org
    ------------------------------



  • 28.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 14:16
    Will you be adjusting the core data sheet/core label accordingly or is only the US label being modified to address FDA's concern? I would evaluate if the company position is to still consider the device to be partially resorbable based on FDA's feedback or if the company agrees with FDA that this terminology is now false or misleading given that there is a non-resorbable component and therefore, should be prohibited from use globally. There is precedent to suggest that the regulatory bodies in the US and EU communicate with each other and therefore, may be informed of the other's concerns and feedback. Also, is the device being marketed in specific member states of the EU? Your local compliance officer (or global compliance officer) should be consulted based on the member state that it's being marketed in as there are certain regions that adopt stricter provisions to ensure more extensive protection against misleading advertising.



    ------------------------------
    Georgina Lee PharmD
    Cambridge MA
    United States
    ------------------------------



  • 29.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 14:21
    It would be important to understand why FDA objected to the language about 'partially resorbable'. If it is because they believe the terminology is confusing and so want to simplify the messaging, that is one aspect. In that case, I would find another way to accurately describe the product. The important aspect is that the product is accurately (and consistently) described, not that the same verbatim terms are used.

    But if they technically do not agree that part is resorbable and part is not, that would be a more difficult issue and you may need to educate your reviewers about the important features of your product.


    ------------------------------
    Julie Batal
    VP, Head of Regulatory Labeling
    Cambridge, MA USA
    ------------------------------



  • 30.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 14:19
    This message was posted on behalf of a user wishing to remain anonymous:

    HI, I have a question for the discussion-
    my company has a tag line we use, that has a footnote to it.
    example:
    Company A
    the #1 provider of drug type - with a foot noted reference.

    When we do promotional materials with the tag line, we always include the footnote and reference.
    However, the  marketing team wants to ​put the Company name and tag line on the front of a tablecloth to be used at displays at conferences and such.
    it will be just the name and tag line, no product info on the cloth itself.
    All the related materials have the reference. the question is, do we need to have the footnote on the tablecloth, and if so, where does the reference info need to be in order to remain compliant?

    *The table cloth will be used at a corporate conference booth, that will have information about the company and the products we sell.
    The footnote is simply the number 1, and then the reference information (usually in the footnote references at the bottom of the promotional piece) states "Data on file, IMS data 2017"

    ------------------------------
    Emily Stamm
    Community Manager
    Regulatory Affairs Professionals Society®
    regex@raps.org
    ------------------------------



  • 31.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 14:26
    Thanks for your question. From what you described, the tablecloth is going to be displayed in an exhibit booth that includes branded products and other separate corporate pieces. I am also going on the assumption you are getting pushback from your marketing team about including the footnote reference on the actual tablecloth.

    If, in your booth, you'll have brochures or similar materials that include the tagline with the footnote *and* also include the reference information, then I would think it would be okay if your tablecloth includes the tagline with the footnote at the end but not have to include an actual footnote. If someone were to stop by the booth and ask "what does that footnote refer to?" you could pull out that brochure and show them the reference and also tell them "this is supported by data from 2017 from IMS." 

    Hope that helps.

    ------------------------------
    Linda Pollitz RAC
    Senior Director, Regulatory Affairs, Advertising & Promotion
    Bedford MA
    United States
    ------------------------------



  • 32.  RE: Ask Me Anything Session: APL

    This message was posted by a user wishing to remain anonymous
    Posted 12-Dec-2018 17:17
    This message was posted by a user wishing to remain anonymous

    Thank you, that's exactly the situation- Marketing does not want the footnote, as it will look "messy", and as Regulatory, I want to be sure we are compliant! 
    I appreciate your input. 



  • 33.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 14:26
    What, if any, limitations exist when sharing marketing materials and claims for a medical device product that is pending 510(k) clearance if a disclaimer is included in those materials stating the pending status?

    ------------------------------
    Julie Meyer
    Regulatory Affairs
    Wayland IA
    United States
    ------------------------------



  • 34.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 14:28
    Who are these marketing materials being shared with? Note that the promotion of prescription-only medical devices to consumers is largely prohibited in the EU member states. If you haven't already, I would review Article 2 of the Council Directive 93/42/EEC concerning medical devices (ie., the medical devices directive or MDD), which states as a general principle that the manufacturer of a medical device may market and promote only medical devices that are CE marked in accordance with the medical devices directive. In other words, if a device is not CE marked then it cannot be promoted in the EU. ​​

    ------------------------------
    Richard Lem
    Whippany NJ
    United States
    ------------------------------



  • 35.  RE: Ask Me Anything Session: APL

    Posted 12-Dec-2018 14:35
    Edited by Emily Stamm 12-Dec-2018 15:57

    Thanks for joining us for this wonderful session, and a big thank you to our experts Linda, Julie, Richard, Georgina, and John.


    As a reminder, you can find the Regulatory Focus Article Series, in Global Advertising, Promotion, and Labeling (APL) Regulations here.

     

    Feel free to keep the conversation going by adding your question to this thread.

    Thanks again!

    Emily



    ------------------------------
    Emily Stamm
    Community Manager
    Regulatory Affairs Professionals Society®
    regex@raps.org
    ------------------------------



  • 36.  RE: Ask Me Anything Session: APL

    Posted 13-Dec-2018 09:43

    Our issue remains providing guidance to marketing on the use of social media with respect to claims and defining a good process to monitor social media for customer feedback. The challenge is not to be overly restricted, but not to expose the company to unnecessary risk by not being able to appropriately monitor the wider expanse of feedback channels.

    Specifically, our MarCom folks want to be active on Facebook, Twitter, Instagram, as well as our own website. This includes posting relevant news related to Women's Health, as well as our own commercially-focused events. While I agree that social media is a great tool for marketing and awareness, they also are portals for customer feedback. Should someone post feedback, positive or negative, on one of our sites, we have an obligation to put that feedback into our Customer Feedback "box" for review by the Quality Team. If someone were to post, regardless if the incident is true or not, that one of our products malfunctioned, we would have an obligation to review and make an AE determination for any regulatory follow-up. This is one of the problem areas....how to ensure that the various channels are being monitored actively enough to ensure we are atop the feedback loop enough so we can respond within the appropriate time frame. I relate this to APL in that social media is a portal for advertising & promotion. How do we encourage MarCom to leverage social media for advertising & promotion, but also to be cognizant that every time they push something out, they are opening up a channel for feedback that needs to be monitored.

    With respect to labeling, if a claim is made on a social media channel, by us or a user, do we have to act if the claim isn't in our indications? For example, if a physician posts about an off-label use of our product, do we ignore it, remove it, or state the mentioned use is off-label. If the latter, you are slapping the hands of a potential use publicly. Perhaps these concerns have been addressed by other users, particularly from smaller companies that have limited resources to actively manage social media. The responses are likely to represent a set of best practices and "lessons learned."



    ------------------------------
    Larry Lugo
    Consultant
    Carlsbad CA
    United States
    ------------------------------



  • 37.  RE: Ask Me Anything Session: APL

    Posted 13-Dec-2018 09:45
    @Larry Lugo,does your company have Social Media Policies and Procedures, and guidelines for expectations around specific types of platforms? If not, you'd be wise to assemble a multidisciplinary team asap in order to develop such SOPs and guidelines, and be sure you get buy-in from senior management (management committee) to ensure sufficient resources will be in place to undertake all activities around social media. SOPs and guidelines should include, among other things, expectations for handling product complaints and adverse events (including timelines for responding real-time). Your guidelines should include prepared responses to various scenarios. For example, if you are accepting user generated content (UGC) and a user posts a use that is off-label, you should have a prepared response that acknowledges the use the user described is off label, what the approved indication is, and any other pertinent information. You should also have guidelines for dealing with filing 2253s if any of the content your company will be posting is branded content. Finally, your guidelines should clearly spell out who is responsible for monitoring the platforms for any UGC to ensure complaints and AEs are reported and investigated timely.




    ------------------------------
    Linda Pollitz RAC
    Senior Director, Regulatory Affairs, Advertising & Promotion
    Bedford MA
    United States
    ------------------------------



  • 38.  RE: Ask Me Anything Session: APL

    Posted 13-Dec-2018 09:45
    I agree with Linda's response and would highly recommend reviewing FDA's guidances on social media (link: https://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm397791.htm) to better understand what falls under the responsibility of the sponsor. I would also collaborate with Legal/Compliance to develop standard disclaimer language for your company to be used on sponsored social media pages regarding the content and activity of your page and discuss legal/regulatory standards between US vs ex-US as well. There are also examples of other companies who choose to disable commenting on social media sites, which I would also take into consideration as you build out your company policies and procedures. Depending on the size of your company, you can also consider working with outside counsel or with a consultant to develop your company policies regarding social media activity including business vs. personal use, global/regional considerations, media relations and operations.

    ------------------------------
    Georgina Lee PharmD
    Cambridge MA
    United States
    ------------------------------